Cite
Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer.
MLA
Priceman, Saul J., et al. “Co-Stimulatory Signaling Determines Tumor Antigen Sensitivity and Persistence of CAR T Cells Targeting PSCA+ Metastatic Prostate Cancer.” OncoImmunology, vol. 7, no. 2, Feb. 2018, p. N.PAG. EBSCOhost, https://doi.org/10.1080/2162402X.2017.1380764.
APA
Priceman, S. J., Gerdts, E. A., Tilakawardane, D., Kennewick, K. T., Murad, J. P., Park, A. K., Jeang, B., Yamaguchi, Y., Yang, X., Urak, R., Weng, L., Chang, W.-C., Wright, S., Pal, S., Reiter, R. E., Wu, A. M., Brown, C. E., & Forman, S. J. (2018). Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. OncoImmunology, 7(2), N.PAG. https://doi.org/10.1080/2162402X.2017.1380764
Chicago
Priceman, Saul J., Ethan A. Gerdts, Dileshni Tilakawardane, Kelly T. Kennewick, John P. Murad, Anthony K. Park, Brook Jeang, et al. 2018. “Co-Stimulatory Signaling Determines Tumor Antigen Sensitivity and Persistence of CAR T Cells Targeting PSCA+ Metastatic Prostate Cancer.” OncoImmunology 7 (2): N.PAG. doi:10.1080/2162402X.2017.1380764.